Golden Green’s Sarepta Therapeutics SRPT Stock Holding History

Golden Green’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,643	Closed	-$280K	–	192
2020 Q4	$280K	Buy	+1,643	New	+$243K	0.26%	89

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Golden Green's SRPT Position: Q1 2021 in Review

Golden Green sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 1,643 shares — an estimated $280K sold.

Golden Green first reported a position in SRPT in Q4 2020 and held it in 1 quarter. The position peaked at $280K in Q4 2020. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

Golden Green reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
Golden Green sold 1,643 Sarepta Therapeutics shares in Q1 2021, an estimated $280K.
Golden Green first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 1 quarter.
Golden Green's Sarepta Therapeutics position peaked at $280K in Q4 2020.
366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Golden Green's 13F filing for Q1 2021, filed 13 Apr 2021.